Skip to main content
. 2023 Feb 24;18(3):791–799. doi: 10.1007/s11739-023-03222-x

Table 2.

Rituximab infusions and adverse events

First infusion of CT-P10 (n = 12) First infusion of oRTX (n = 16) p value oRTX/CT-P10 (n = 52) Remain on oRTX (n = 48) p value
Rituximab dosage scheme, n (%)
 1 g × 2 weeks 9 (75.0) 13 (81.2) 0.532 32 (61.5) 27 (56.3) 0.775
 1 g (single dose) 2 (16.7) 2 (12.5) 15 (28.8) 13 (27.1)
 500 mg × 2 weeks 1 (6.3) 2 (3.8) 3 (6.3)
 500 mg (single dose) 1 (8.3) 3 (5.8) 5 (10.4)
Cumulative dose of rituximab (g), median (IQR) N/A 9 (10.1) 10 (11.8) 0.222
Infusion duration (hour), median (IQR) 4.5 (0.5) 4.3 (1.1) 0.229 3.5 (0.6) 3.5 (0.5) 0.063
Infusion duration, n (%)
  ≤ 2.5 h N/A 4 (8.7) 4 (8.9) N/A
 2.5–4 h 1 (8.3) 7 (43.8) 36 (78.3) 32 (71.1)
  ≥ 4 h 11 (91.7) 9 (56.3) 6 (13.0) 9 (20.0)
Infusion-related reactions, n (%) 2 (16.7) 6 (37.5) 0.343 23 (44.3) 24 (50.0) 0.770
 Grade 1 2 (12.5) 11 (21.2) 13 (27.1)
 Grade 2 2 (16.7) 4 (25.0) 12 (23.1) 11 (22.9)
Hypogammaglobulinemiaa, n (%)
 Ig G < 7.51 g/L 1 (20.0) 1 (10.0) N/A 9 (29.0) 3 (10.7) 0.155
 IgA < 0.82 g/L 1 (20.0) 2 (8.3) 4 (21.1) 0.380
 Ig M < 0.46 g/L 1 (25.0) 1 (11.1) 10 (47.6) 9 (37.5) 0.702
Infectionsb, n (%) 2 (18.2) 5 (35.7) N/A 19 (39.6) 14 (33.3) 0.693
 Upper respiratory tract infection 1 3 5
 Urinary tract infection 2 1 9 7
 Pneumonia 1 1
 COVID-pneumonia 1 5 4
 Soft tissue infection 1 1
 Herpes zoster 1 1
Hospitalization due to infection, n (%) 1 (9.1) 2 (14.3) N/A 5 (10.4) 4 (9.5) N/A
 COVID-pneumonia 1 5 4
 Urinary tract infection 1
 Soft tissue infection 1

a74 patients’ files had data on immunoglobulins

b115 patients’ files had data on infections